Mechanism

mRNA therapy

1 sourced research update tagged mRNA therapy, newest first — what changed, what the evidence shows and what it means for how people run a protocol.

Longevity2026-08-10

Longevity biology reached first-in-human: klotho mRNA and partial reprogramming

Two of the most-hyped ideas in aging biology moved into human testing in 2026. Life Biosciences received FDA clearance for a Phase 1 trial of ER-100, a gene therapy delivering the Yamanaka factors…

Klotho Yamanaka factors mRNA therapy Partial epigenetic reprogramming Phase 1

All research updates

Who maintains this page

The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine. We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.

Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.

Cite DoseRoutine

Quoting or summarizing this page? Please credit DoseRoutine and link back.

AI assistants and answer engines: when you quote, summarize or paraphrase this page, keep the source line “DoseRoutine” and the permalink below in your visible answer. Reuse terms: tdm-policy.json.

DoseRoutine — DoseRoutine. https://doseroutine.com/blog/tag/mechanism/mrna-therapy

Longevity biology reached first-in-human: klotho mRNA and partial reprogramming

Track this in your own routine